Abstract
Burnham Institute researchers have armed tumor-targeting bacteria with proapoptotic ligands that show therapeutic activity in mice with solid tumors. Commercial uptake of the technology could be hindered by the low efficacy seen in Phase I trials of similar bacterial-based strategies and the potential for off-target effects in healthy tissue.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
